| 12 months dual antiplatelet versus 6 months dual antiplatelet | |||
| ISAR-SAFE, 2009 NCT00661206 | additional 6 month period of clopidogrel versus placebo | Patients on clopidogrel therapy at least 6 months after DES implantation, who do not require a reintervention | double blind Follow-up duration: 12 months |
| 24 months of dual antiplatelet treatment versus 6 months dual antiplatelet | |||
| PRODIGY, 2011 NCT00611286 | 24 months of dual antiplatelet treatment (clopidogrel plus aspirin) versus 6 months of dual antiplatelet treatment (clopidogrel plus aspirin) | patients (74 with acute coronary syndromes and 26 with stable angina) who underwent stenting | open Follow-up duration: 2 years |
| 6-month dual antiplatelet therapy versus 12 months dual antiplatelet | |||
| EXCELLENT, 2011 NCT00698607 | dual antiplatelet therapy for six months versus dual antiplatelet therapy for one year | patients with coronary artery disease | |
| cilostazol versus aspirin | |||
| Kunishima, 1997 | Cilostazol 200 mg qD unspecified durationg qD versus Aspirin 81 mg qD | ||
| cilostazol + aspirin versus aspirin | |||
| Sekiya, 1998 | Cilostazol 200 mg qD x6mos Aspirin 81 mg qD versus Coumadin unspecified regimen Aspirin 81 mg qD | ||
| cilostazol + aspirin versus ticlopidine + aspirin | |||
| Kozuma, 2001 | Cilostazol 200 mg qD x6 mos Aspirin 81–162 mg qD versus Ticlopidine 200 mg qD x6 mos Aspirin 81–162 mg qD | ||
| Ochiai, 1999 | Cilostazol 100 mg BID x6 mos Aspirin 81 mg TID versus Ticlopidine 100 mg BID x1 mo Aspirin 81 mg TID | ||
| Park, 1999 | Cilostazol 100 mg BID x6 mos Aspirin 200 mg qD versus Ticlopidine 250 mg BID x4 wks Aspirin 200 mg qD | ||
| Yoon, 1999 | Cilostazol 100 mg BID x30 days Aspirin 100 mg qD versus Ticlopidine 250 mg BID x30 days Aspirin 100 mg qD | ||
| Kamishirado, 2002 | Cilostazol 200 mg qD x6 mos Aspirin 81 mg qD versus Ticlopidine 200 mg qD x6 mos Aspirin 81 mg qD | ||
| clopidogrel + aspirin versus ticlopidine + aspirin | |||
| Müller, 2000 | Clopidogrel 75 mg qD x4 wks Aspirin 100 mg qD versus Ticlopidine 250 mg BID x4 wks Aspirin 100 mg qD | ||
| CLASSICS, 2000 | Clopidogrel 300mg x1, 75 mg qD x4 wks Aspirin 325 mg qDypñ ·` versus Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD | ||
| TOPPS, 2001 | Clopidogrel 300 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD versus Ticlopidine 500 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD | ||
| Piamsomboon, 2001 | Clopidogrel 300 mg x1, 75 mg qD x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD versus Ticlopidine 250 mg po BID x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD | ||
| clopidogrel+aspirin versus aspirin | |||
| REAL-LATE, ZEST-LATE, 2010 NCT00484926 | clopidogrel plus aspirin versus aspirin alone | patients who had received drugeluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months | open Follow-up duration: 19.2 months South Korea |
| Endeavor stent and three months of DAPT versus standard 12-month DAPT and other DES | |||
| RESET, NCT01145079 | versus | ||
| high-dose clopidogrel versus normal-dose clopidogrel | |||
| GRAVITAS, 2011 NCT00645918 | High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) versus regular clopidogrel dose | patients receiving drug-eluting stents with high residual platelet activity (PRU>=230) on the regular clopidogrel dose (platelet-function tests with the VerifyNow assay 12 to 24 hours after PCI) | open Follow-up duration: 6 months North America |
| prolonged dual antiplatelet therapy versus 12 months dual antiplatelet | |||
| DES-LATE, 2010 NCT00484926 | dual antiplatelet therapy (clopidogrel plus aspirin) versus aspirin alone | patients who had received drug eluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months | open Follow-up duration: 19.2 mo South Korea |
| ticlopidine + aspirin versus aspirin | |||
| STARS (vs aspirin), 1998 | Ticlopidine 250 mg BID 4 wks Aspirin 325 mg qDDage/pj versus Aspirin 325 mg qD | ||
| Hall, 1996 | Ticlopidine 250 mg BID 1 mo Aspirin 325 mg qD 5 days versus Aspirin 325 mg qD | ||
| ticlopidine + aspirin versus coumadin + aspirin | |||
| STARS (vs coumadin+asp), 1998 | Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD versus Coumadin INR 2–2.5 x4 wks Aspirin 325 mg qDBID | ||
| FANTASTIC, 1998 | Ticlopidine 250 mg BID 6 wks Aspirin 100–325 mg qD versus Coumadin INR† 2.5–3.0 6 wks Aspirin 100–325 mg qD/pj | ||
| ISAR, 1996 | Ticlopidine 250 mg BID 4 wks Aspirin 100 mg BIDage/pj versus Coumadin INR 3.5–4.5 4 wks Aspirin 100 mg BID | ||
| MATTIS, 1998 | Ticlopidine 250 mg BID 30 days Aspirin 250 mg qD versus Coumadin INR 2.5–3.0 x30 days Aspirin 250 mg qDg qD/pj | ||
| Foussas, 2000 | Ticlopidine 500mg qD 1 mo Aspirin 325 mg qD versus Coumadin INR 2–3 x4 wks Aspirin 325 mg qDg BID | ||
| triple antiplatelet versus dual antiplatelet therapy | |||
| CILON-T, 2010 | triple antiplatelet therapy with aspirin, clopidogrel, and cilostazol for 6 month versus dual antiplatelet therapy | real-world patients undergoing PCI | Follow-up duration: 6 mo |
| triple therapy versus dual antiplatelet therapy | |||
| WOEST, NCT00769938 | oral anticoagulants, aspirin and clopidogrel versus oral anticoagulants, clopidogrel | ||
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
